11/10
➡️Up next, PISCES, the use of fish oil to decrease mortality in dialysis patients 🐟
pubmed.ncbi.nlm.nih....
👋 #NephJC #Skytorial by @msocomd.bsky.social
Join us @nephjc.bsky.social
See you soon!

11/10
➡️Up next, PISCES, the use of fish oil to decrease mortality in dialysis patients 🐟
pubmed.ncbi.nlm.nih....
👋 #NephJC #Skytorial by @msocomd.bsky.social
Join us @nephjc.bsky.social
See you soon!

10/10
Final #NephJC thoughts
The pace at which IgAN therapies are evolving proves that nephrology can innovate. What was once supportive care is now targeted treatment. Exciting times ahead!
Therapeutics are evolving quickly, try to keep up 🏃

10/10
Final #NephJC thoughts
The pace at which IgAN therapies are evolving proves that nephrology can innovate. What was once supportive care is now targeted treatment. Exciting times ahead!
Therapeutics are evolving quickly, try to keep up 🏃

9/10
I want more info: Check out #NephJC summary by @notjustdialysis.bsky.social
✅ www.nephjc.com/news/...
Visual abstracts by @salinesolut.bsky.social
✅

8/10
#NephJC Quote of the fortnight

We are with you @brianrifkin.bsky.social 💯!!!

7/10
Chat consensus?
We’re in an exciting era for IgAN therapeutics – so many new, effective options are emerging. But it’s not all smooth sailing: cost 💰 and global access 🌍 remain major hurdles, meaning not every patient can benefit yet. Balancing innovation with equity will be key.

6/10
Give me something clever to say 🤓
IgAN is no longer one-size-fits-all.
Timing matters.
Excitingly, tailored treatment is slowly becoming a reality.
@doctorgates.bsky.social

5/10
A figure paints🖼️ a 1000 words!
Emerging evidence from APRIL/BAFF–axis trials underscores how central this pathway is to IgAN biology. Let’s put ORIGIN side by side with the others and see what we learn!

4/10
One post results
203 pts (106 atacicept and 97 placebo)
Week 36: UPCR reduction was 45.7% (atacicept) vs 6.8% placebo); geometric mean difference 41.8 percentage points (95% CI 28.9–52.3; P<0.001)
AEs: 59.3% atacicept vs 50% placebo; mostly mild/moderate

3/10 One post methods
🌍 Phase 3, multicenter, double-blind RCT
💉 IgAN pts randomized 1:1 → atacicept 150 mg SC weekly (self-admin) vs placebo
📉 Primary endpoint: % change in 24-hr UPCR at wk 36

2/10
What'd I miss?
Amazing how quickly IgAN guidelines have evolved – 2021 to 2025 has been a whirlwind! And what was once just a ‘future research direction’ is now front-and-center with real data. Feels like we’re witnessing the “ORIGIN” story of a new era in IgAN therapeutics!

This says it all! #NephJC

It seems counterintuitive to give ACEi and SGLT2i which are just trying to decrease proteinuria (mask symptoms), rather than turning off the disease at the source.
Unfortunately in the real world, cost does matter. #NephJC